Trials / Completed
CompletedNCT00381381
The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease
A Multi-center Study for the Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 199 (actual)
- Sponsor
- Eisai Korea Inc. · Industry
- Sex
- All
- Age
- 60 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This study attempts to differentiate the clinical responses of Choline Acetyltransferase and Apolipoprotein Epsilon gene polymorphism to donepezil in Alzheimer's Disease patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Donepezil | 2.5mg once daily for the first 7 days, 5mg once daily for the next 3 weeks, after then the dose can be increased 10mg once daily under the investigator's decision. |
Timeline
- Start date
- 2006-05-31
- Primary completion
- 2008-08-31
- Completion
- 2008-12-31
- First posted
- 2006-09-27
- Last updated
- 2022-01-04
- Results posted
- 2012-07-27
Locations
15 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00381381. Inclusion in this directory is not an endorsement.